A large-scale genetic study found 26 risk loci for epilepsy, a chronic brain disease with multiple forms, not all of them heritable. The work, by more than 300 authors from the International League Against Epilepsy (ILAE), investigated seven different subtypes of this neurological condition. “There are over 100 genes that we know can harbor mutations that cause epilepsy,” the co-corresponding author Gianpiero Cavalleri told BioWorld. These genes have rare forms that cause that epilepsy. However, “this particular GWAS is focused more on common forms of epilepsy,” he said. Read More
Microtubule-targeting agents impact microtubule dynamics to induce mitotic arrest and tumor cell death. Tubulin is therefore a relevant target for the discovery of new agents acting as tumor neovasculature disruptors. Researchers from Nanjing Keygen Biotech Co. Ltd. have reported on the design and optimization of novel tubulin polymerization inhibitors with antiangiogenesis activity that led to the identification of [I] as the compound. Read More
Tetra Pharm Technologies Aps has completed preclinical testing and announced promising in vivo study results with its candidate compound, TPT-0301, which targets the endocannabinoid system. Read More
Antoxa Corp. and Swiftpharma BV have signed an exclusive collaboration agreement to support the development and commercialization of a plant-made monoclonal antibody against ricin exposure. Read More
Researchers from the MD Anderson Cancer Center presented data from a study that assessed the tumor microenvironment (TME) of adenoid cystic carcinoma (ACC) with the aim of identifying novel therapeutic targets for ACC. Read More
Google’s Scott Penberthy joins the podcast for a visionary discussion that scans the horizon for startling changes artificial intelligence will bring to drug development in the relatively near future. Read More
Shenzhen Forward Pharmaceuticals Co. Ltd. has synthesized quinazoline derivatives acting as GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer, particularly lung cancer. Read More
Xtalpi Inc. and Parthenon Therapeutics Inc. (now known as Incendia Therapeutics Inc.) have entered into a collaboration to discover novel therapeutic antibodies for the treatment of solid tumors. Read More
Beigene Ltd. has identified heterocyclic compounds acting as E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of hematologic cancer and glioblastoma. Read More
Vertex Pharmaceuticals Inc. has divulged cystic fibrosis transmembrane conductance regulator (CFTR) modulators reported to be useful for the treatment of cystic fibrosis. Read More
Work at Bristol Myers Squibb Co. has led to the discovery of selective Toll-like receptor 7 (TLR7) agonists with potential as anticancer agents. Read More
Etern Biopharma (Shanghai) Co. Ltd. has described bicyclic heteroaryl compounds acting as transcriptional coactivator YAP1 and/or TAZ/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer, fibrosis and cardiovascular disorders. Read More
